The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)
Conclusions: We have derived a VTE risk assessment model specifically for patients with MM starting IMID therapy. The HAS-RiSC score combines 7 clinical risk factors - History of VTE, Age 80+, Surgery within last 90 days, Race Black, race Asian, Steroid use, and Chemotherapy - into a simplified VTE risk assessment model that identifies a subgroup of patients at very high risk for VTE. External validation of this risk assessment model is currently in progress.DisclosuresGarcia: Daiichi Sankyo: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Research Funding; Pfizer: Consultancy; Retham Technologies LLC: Consultancy; Shingoi: Consultancy; Portola: Research Funding; Bristol Meyers Squibb: Consultancy; Boehringer Ingelheim: Consultancy. Lyman: Amgen: Other: Research support; Generex Biotechnology: Membership on an entity's Board of Directors or advisory committees; Halozyme; G1 Therapeutics; Coherus Biosciences: Consultancy.
Source: Blood - Category: Hematology Authors: Li, A., Wu, Q. V., Warnick, G., Zakai, N. A., Libby, E. N., Garcia, D. A., Lyman, G. H. Tags: 331. Pathophysiology of Thrombosis: Cancer- and Children-Associated Thrombosis Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Children | Coumadin | Databases & Libraries | Dexamethasone | Epidemiology | Medicare | Myeloma | Pfizer | Revlimid | Statistics | Study | Thrombosis | Transplants | Velcade | Warfarin